Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Annals of Surgical Oncology
Published in: Annals of Surgical Oncology 8/2013

01-08-2013 | Gastrointestinal Oncology

C4.4A Expression Is Associated with a Poor Prognosis of Esophageal Squamous Cell Carcinoma

Authors: Masahisa Ohtsuka, MD, Hirofumi Yamamoto, MD, PhD, Toru Masuzawa, MD, PhD, Hidekazu Takahashi, MD, PhD, Mamoru Uemura, MD, PhD, Naotsugu Haraguchi, MD, PhD, Junichi Nishimura, MD, PhD, Taishi Hata, MD, PhD, Makoto Yamasaki, MD, PhD, Hiroshi Miyata, MD, PhD, Ichiro Takemasa, MD, PhD, Tsunekazu Mizushima, MD, PhD, Shuji Takiguchi, MD, PhD, Yuichiro Doki, MD, PhD, FACS, Masaki Mori, MD, PhD, FACS

Published in: Annals of Surgical Oncology | Issue 8/2013

Login to get access

Abstract

Background

C4.4A is a glycolipid-anchored membrane protein expressed in several human malignancies. We examined clinical relevance of C4.4A expression in 111 esophageal squamous cell carcinoma (ESCC) tissue samples.

Methods

Anti-human C4.4A antibody that recognizes the glycosylphosphatidyl inositol (GPI) anchor signaling sequence (C4.4A-GPI Ab) and anti-human C4.4A-119 polyclonal antibody (C4.4A-119 Ab) were used for immunohistochemistry and Western blot testing.

Results

Both antibodies detected the C4.4A protein expression at the parabasal layer of normal epithelium of the esophagus. In tumor tissues, the C4.4A protein was detected in 66 (59.5 %) and 95 (85.6 %) of 111 ESCCs by the C4.4A-GPI Ab and the C4.4A-119 Ab, respectively. The C4.4A-GPI Ab mainly detected membranous C4.4A expression (83.3 %, 55 of 66 positive cases), while the C4.4A-119 Ab exclusively detected cytoplasmic C4.4A expression (100 %, 73 cytoplasm alone and 22 cytoplasm plus membrane in 95 positive cases). Western blot analysis indicated that normal epithelium expressed the band of C4.4A at 70 kDa, whereas the tumor tissues displayed the band at the lower molecular weight. Survival analysis indicated that the C4.4A-positive ESCCs had significantly worse 5-year overall survival than the C4.4A-negative ESCC samples (P = 0.021) when using the C4.4A-GPI Ab, but not when using the C4.4A-119 Ab. This difference was most evident with membranous expression of C4.4A (P = 0.005).

Conclusions

C4.4A expression was associated with a poor prognosis of ESCC when the GPI-related antibody was used. On the other hand, the C4.4A-119 Ab may be a useful diagnostic tool for ESCC because of its high detection rate.
Literature
1.
Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010;127:2893–917.PubMedCrossRef
2.
Holmes RS, Vaughan TL. Epidemiology and pathogenesis of esophageal cancer. Semin Radiat Oncol. 2007;17:2–9.PubMedCrossRef
3.
Taccioli C, Chen H, Jiang Y, et al. Dietary zinc deficiency fuels esophageal cancer development by inducing a distinct inflammatory signature. Oncogene. 2012;31:4550–8.PubMedCrossRef
4.
Matzku S, Wenzel A, Liu S, Zoller M. Antigenic differences between metastatic and nonmetastatic BSp73 rat tumor variants characterized by monoclonal antibodies. Cancer Res. 1989;49:1294–9.PubMed
5.
Claas C, Herrmann K, Matzku S, Moller P, Zoller M. Developmentally regulated expression of metastasis-associated antigens in the rat. Cell Growth Differ. 1996;7:663–78.PubMed
6.
Rosel M, Claas C, Seiter S, Herlevsen M, Zoller M. Cloning and functional characterization of a new phosphatidyl-inositol anchored molecule of a metastasizing rat pancreatic tumor. Oncogene. 1998;17:1989–2002.PubMedCrossRef
7.
Wurfel J, Seiter S, Stassar M, et al. Cloning of the human homologue of the metastasis-associated rat C4.4A. Gene. 2001;262:35–41.PubMedCrossRef
8.
Smith BA, Kennedy WJ, Harnden P, Selby PJ, Trejdosiewicz LK, Southgate J. Identification of genes involved in human urothelial cell–matrix interactions: implications for the progression pathways of malignant urothelium. Cancer Res. 2001;61:1678–85.PubMed
9.
Hansen LV, Gardsvoll H, Nielsen BS, et al. Structural analysis and tissue localization of human C4.4A: a protein homologue of the urokinase receptor. Biochem J. 2004;380(Pt 3):845–57.PubMedCrossRef
10.
Seiter S, Stassar M, Rappl G, Reinhold U, Tilgen W, Zoller M. Upregulation of C4.4A expression during progression of melanoma. J Invest Dermatol. 2001;116:344–7.PubMedCrossRef
11.
Fletcher GC, Patel S, Tyson K, et al. hAG-2 and hAG-3, human homologues of genes involved in differentiation, are associated with oestrogen receptor-positive breast tumours and interact with metastasis gene C4.4A and dystroglycan. Br J Cancer. 2003;88:579–85.PubMedCrossRef
12.
Hansen LV, Skov BG, Ploug M, Pappot H. Tumour cell expression of C4.4A, a structural homologue of the urokinase receptor, correlates with poor prognosis in non–small cell lung cancer. Lung Cancer. 2007;58:260–6.PubMedCrossRef
13.
Paret C, Hildebrand D, Weitz J, et al. C4.4A as a candidate marker in the diagnosis of colorectal cancer. Br J Cancer. 2007;97:1146–56.PubMedCrossRef
14.
Konishi K, Yamamoto H, Mimori K, et al. Expression of C4.4A at the invasive front is a novel prognostic marker for disease recurrence of colorectal cancer. Cancer Sci. 2010;101:2269–77.PubMedCrossRef
15.
Oshiro R, Yamamoto H, Takahashi H, et al. C4.4A is associated with tumor budding and epithelial–mesenchymal transition of colorectal cancer. Cancer Sci. 2012;103:1155–64.PubMedCrossRef
16.
Yamamoto H, Oshiro R, Ohtsuka M, et al. Distinct expression of C4.4A in colorectal cancer detected by different antibodies. Int J Oncol. 2013;42:197–201.PubMed
17.
Hayashi N, Yamamoto H, Hiraoka N, et al. Differential expression of cyclooxygenase-2 (COX-2) in human bile duct epithelial cells and bile duct neoplasm. Hepatology. 2001;34(4 Pt 1):638–50.PubMedCrossRef
18.
Noura S, Yamamoto H, Ohnishi T, et al. Comparative detection of lymph node micrometastases of stage II colorectal cancer by reverse transcriptase polymerase chain reaction and immunohistochemistry. J Clin Oncol. 2002;20:4232–41.PubMedCrossRef
19.
Takemasa I, Yamamoto H, Sekimoto M, et al. Overexpression of CDC25B phosphatase as a novel marker of poor prognosis of human colorectal carcinoma. Cancer Res. 2000;60:3043–50.PubMed
20.
Yamamoto H, Soh JW, Shirin H, et al. Comparative effects of overexpression of p27Kip1 and p21Cip1/Waf1 on growth and differentiation in human colon carcinoma cells. Oncogene. 1999;18:103–15.PubMedCrossRef
21.
Hansen LV, Laerum OD, Illemann M, Nielsen BS, Ploug M. Altered expression of the urokinase receptor homologue, C4.4A, in invasive areas of human esophageal squamous cell carcinoma. Int J Cancer. 2008;122:734–41.PubMedCrossRef
22.
Sjoquist KM, Burmeister BH, Smithers BM, et al. Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: an updated meta-analysis. Lancet Oncol. 2011;12:681–92.PubMedCrossRef
23.
Stahl M, Walz MK, Stuschke M, et al. Phase III comparison of preoperative chemotherapy compared with chemoradiotherapy in patients with locally advanced adenocarcinoma of the esophagogastric junction. J Clin Oncol. 2009;27:851–6.PubMedCrossRef
24.
Ando N, Kato H, Igaki H, et al. A randomized trial comparing postoperative adjuvant chemotherapy with cisplatin and 5-fluorouracil versus preoperative chemotherapy for localized advanced squamous cell carcinoma of the thoracic esophagus (jcog9907). Ann Surg Oncol. 2012;19:68–74.PubMedCrossRef
25.
Esselens CW, Malapeira J, Colome N, Moss M, Canals F, Arribas J. Metastasis-associated C4.4A, a GPI-anchored protein cleaved by ADAM10 and ADAM17. Biol Chem. 2008;389:1075–84.PubMedCrossRef
Metadata
Title
C4.4A Expression Is Associated with a Poor Prognosis of Esophageal Squamous Cell Carcinoma
Authors
Masahisa Ohtsuka, MD
Hirofumi Yamamoto, MD, PhD
Toru Masuzawa, MD, PhD
Hidekazu Takahashi, MD, PhD
Mamoru Uemura, MD, PhD
Naotsugu Haraguchi, MD, PhD
Junichi Nishimura, MD, PhD
Taishi Hata, MD, PhD
Makoto Yamasaki, MD, PhD
Hiroshi Miyata, MD, PhD
Ichiro Takemasa, MD, PhD
Tsunekazu Mizushima, MD, PhD
Shuji Takiguchi, MD, PhD
Yuichiro Doki, MD, PhD, FACS
Masaki Mori, MD, PhD, FACS
Publication date
01-08-2013
Publisher
Springer US
Published in
Annals of Surgical Oncology / Issue 8/2013
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-013-2900-2

Other articles of this Issue 8/2013

Annals of Surgical Oncology 8/2013 Go to the issue

Gastrointestinal Oncology

The Prognostic Nutritional Index Predicts Long-term Outcomes of Gastric Cancer Patients Independent of Tumor Stage

Breast Oncology

MRI Utilization in Newly Diagnosed Breast Cancer: A Survey of Practicing Surgeons

Endocrine Tumors

Telementoring: A Multi-institutional Experience with the Introduction of a Novel Surgical Approach for Adrenalectomy

Colorectal Cancer

Oncologic Outcomes and Perioperative Clinicopathologic Results after Robot-assisted Tumor-specific Mesorectal Excision for Rectal Cancer

Thoracic Oncology

Prospective Study of Adjuvant Radiotherapy on Preventing Lymph Node Metastasis After Ivor-Lewis Esophagectomy in Esophageal Cancer

Breast Oncology

Analysis of Factors that Influence the Accuracy of Magnetic Resonance Imaging for Predicting Response after Neoadjuvant Chemotherapy in Locally Advanced Breast Cancer